U.S. Actinic Keratosis Treatment Market Size, Share & Trends Analysis Report By Therapy (Topical/Drugs, Surgery, Photodynamic Therapy), By Drug Class, By Product, By End-use- Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2023-2032

The U.S. actinic keratosis treatment market size accounted for USD 2.5 billion in 2022 and is estimated to achieve a market size of USD 3.39 billion by 2032 growing at a CAGR of 3.09% from 2023 to 2032.

Key Pointers:

• The surgery segment held the largest share of 76.60% in 2022 and is anticipated to continue leading during the projected period.
• Based on topical/drugs segment, the nucleoside metabolic inhibitors dominated the market and is projected to hold a significant market share during the forecast period.
• 5-fluorouracil was the leading segment in 2022 having a 31.39% share of AK drugs in the country. 
• The hospitals segment captured the largest revenue share of 30.9% in 2022.
• The nucleoside metabolic inhibitors segment accounted for the largest market in 2022 due to the strong commercial performance of Fluroplex, Carac, and Efudex along with a higher demand for topical formulations to treat the initial stages of the disease
• The hospitals segment was the largest in 2022 owing to increasing physician-assisted procedures performed in hospitals

Report Scope of the U.S. actinic keratosis treatment Market

The increasing prevalence of actinic keratosis, the increased risk of developing skin cancer, and the surge in the geriatric population of the country are the major driving growth factors. For instance, according to a report published in JAMA Dermatology, actinic keratosis affects around three of every 10 older Medicare recipients. Moreover, the presence of potential investigational candidates in the pipeline and the rising R&D efforts from pharmaceutical companies to develop novel treatment approaches for actinic keratosis are likely to contribute to market expansion over the forecast period.

The wide availability of actinic keratosis therapeutic services and the surge in awareness for actinic keratosis (AK) treatment are anticipated to drive market growth. Moreover, the strong demand for minimally invasive therapies for AK and escalated adoption of topical regimens are expected to support market growth. For instance, according to the National Institute for Health and Care Research, 5% fluorouracil cream is the most preferred and best first-line treatment for actinic keratosis.

The growing consumer awareness about dermatological diseases, such as AK, is a major growth booster for the market. An increase in knowledge about diagnostics and treatment strategies for the disease has driven the overall adoption of AK treatment. Field-directed treatments, such as 5-fluorouracil, diclofenac, and imiquimod are expected to witness greater market penetration over the coming years. For instance, clinical trials demonstrated that the patients treated with imiquimod-containing formulation achieved a clearance of around 76%.

Moreover, higher safety and tolerability factors associated with topical actinic keratosis preparations have increased the demand for topical drugs to treat actinic keratosis. For instance, according to phase-3 clinical trials of topical agents for AK published at clinicaltrials.gov, no severe adverse effects were noted from topical AK therapies. Some formulations produced some local skin irritations like allergies but novel topical preparations such as tirbanibulin, and ingenol mebutate showed more favorable tolerability profiles, which is expected to increase the market growth.

According to the NIH, the combination of photodynamic therapy with topical formulations improves the clearance rates as compared to monotherapy alone. Moreover, according to the study published in Healio, the combination therapy of aminolevulinic acid 20% and PDT has shown positive outcomes with fewer side effects in AK. Thus, a strong promise from combination therapies in the treatment of actinic keratosis is anticipated to propel the market growth during the forecast period.

Moreover, leading participants are undertaking strategic initiatives such as product launches, expansion, and partnerships among other strategies to increase their market share. For instance, in February 2022 Athenex, Inc. a leading biopharmaceutical company launched Klisyri for the treatment of actinic keratosis of the scalp in the U.S. Along with this launch, the company announced the licensing of additional territories for tirbanibulin to its partner PharmaEssentia Corp. 

Some of the prominent players in the U.S. actinic keratosis treatment Market include:

• Bausch Health Companies, Inc.
• LEO Pharma A/S
• Almirall, S.A
• Biofrontera AG
• GALDERMA
• Sun Pharmaceutical Industries Ltd
• Novartis AG
• Hill Dermaceuticals, Inc.
• 3M
• Viatris, Inc.

Segments Covered in the Report

This report forecasts the volume and revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor has segmented the U.S. actinic keratosis treatment market.

By Therapy 

• Topical/Drugs
• Surgery
  • Cryotherapy
  • Others
• Photodynamic Therapy

By Drug Class 

• Nucleoside metabolic inhibitors
• Nonsteroidal anti-inflammatory drugs
• Immune response modifiers
• Photoenhancers
• Others

By Product

• 5-fluorouracil
  • Carac
  • Fluoroplex
  • Actikerall
  • Tolak
  • Others
• Diclofenac
  • Solaraze
  • Voltaren
  • Pennsaid
  • Others
  • Imiquimod
  • Aldara
  • Zyclara
  • Others
• Tirbanibulin
• Capecitabine
  • Xeloda
  • Others
• Aminolevulinic acid
  • Ameluz
  • Levulan
• Porfimer sodium
• Others
  • Gemzar
  • Clolar
  • Vidaza
  • Metvix
  • Others

By End-use 

• Hospitals
• Private clinics
• Homecare
• Others